Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

Filmora, a popular video editing software, has become a trusted tool for professionals and beginners. Its logo is an ...

Joining Ramu NiCo as an Asset Protection Officer is a blessing not just for Kenneth Kowi but for his whole family.